Table 1 Baseline demographics, overview of antibiotic courses, outcome variables
Phase I (91 days) | Phase II (110 days) | p-value | |
|---|---|---|---|
Admissions | 174 | 185 | 0.48 |
Hospitalisation days | 952 | 1186 | 0.84 |
Hospitalisation days / admissiona | 5.47 (1/3/41) | 6.41 (1/3/71) | 0.24 |
Fatal casualities | 0 | 3 | 0.25 |
Infection-related fatal casualities | 0 | 0 | 1 |
Sex (% male) | 58% | 60.5% | 0.23 |
Age at admissionb | 6 mt (0–16 yrs) | 7 mt (0–16 yrs) | 0.48 |
Cardiosurgery admissions | 67.8% | 57.8% | 0.05 |
Cardiology admissions | 13.2% | 20.5% | 0.06 |
Respiratory admissions | 10.3% | 13.5% | 0.35 |
Other admissionsc | 8.6% | 8.1% | 0.86 |
Antibiotic courses total | 194 | 182 | 0.14 |
Prophylaxis courses | 66.5% | 55.5% | 0.02* |
Non-proven infection courses | 27.3% | 31.3% | 0.39 |
Proven infection courses | 6.2% | 13.2% | 0.02* |
Secondary antibiotic courses total | 8.2% | 6% | 0.59 |
Secondary courses for prophylaxis | 2.1% | 1.1% | 0.68 |
Secondary courses for non-proven infection | 4.1% | 4.4% | 0.90 |
Secondary courses for proven infection | 2.1% | 0.5% | 0.37 |
Infection relapse rate (non-proven + proven) | 6.2% | 5.0% | 0.62 |